The Department of Health and Human Services finalized a rule Wednesday that would require drugmakers to disclose a drug’s cost if its price before rebates and discounts is above $35 for a month’s supply or the usual course of therapy. The rule is the first move by regulators to implement a blueprint to lower drug prices laid out last year by President Trump.

Source: Los Angeles Times May 08, 2019 15:45 UTC